872365-14-5

Basic information

• Product Name: Fevipiprant
• Synonyms: Fevipiprant;Fevipipran;NVP-QAW039;Fevipiprant(NVP-QAW039);QAW039;Fevipiprant (QAW039);2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid
• CAS NO: 872365-14-5
• Molecular Formula: C19H17F3N2O4S
• Molecular Weight: 426.4094896
• Mol File: 872365-14-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 637.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.44±0.1 g/cm3(Predicted)
• PKA: 3.33±0.30(Predicted)
• CAS DataBase Reference: Fevipiprant(CAS DataBase Reference)
• NIST Chemistry Reference: Fevipiprant(872365-14-5)
• EPA Substance Registry System: Fevipiprant(872365-14-5)

Safety Data

• Hazardous Substances Data: 872365-14-5(Hazardous Substances Data)

Usage

Description

Fevipiprant is a novel oral prostaglandin D2 receptor 2 (DP2; known as CRTh2) antagonist, which is currently in development for the treatment of severe asthma and atopic dermatitis. It has been successful in targeting severe eosinophilic asthma and is used in the oral treatment of this condition.

Uses

Used in Pharmaceutical Industry:
Fevipiprant is used as an oral treatment for asthma, specifically targeting severe eosinophilic asthma. It works by antagonizing the prostaglandin D2 receptor 2 (DP2; known as CRTh2), which helps in managing the symptoms and improving the quality of life for patients with this condition.
Additionally, Fevipiprant is in development for the treatment of atopic dermatitis, a chronic inflammatory skin condition, further expanding its potential applications in the pharmaceutical industry.

Upstream product

• 90176-80-0 2-(trifluoromethyl)-4-fluorobenzaldehyde 
• 1215310-75-0 4-(methylsulfonyl)-2-(trifluoromethyl)benzaldehyde oxime 
• 1215323-17-3 (4-(methylsulfonyl)-2-(trifluoromethyl)phenyl)methanol 
• 934557-65-0 1-(bromomethyl)-4-(methylsulfonyl)-2-(trifluoromethyl)benzene 
• 7546-52-3 (2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid methyl ester 
• 886496-75-9 1-(bromomethyl)-4-chloro-2-(trifluoromethyl)benzene 
• 13534-99-1 2-Amino-3-bromopyridine 
• 23612-48-8 2-methyl-1H-pyrrolo[2,3-b]pyridine 
• 13534-89-9 2,3-dibromopyridine 
• 7546-48-7 N,N-dimethyl-1-(2-methyl-1H-pyrrolo[2,3-b] pyridin-3-yl)methanamine 
• 4414-86-2 3-cyanomethyl-2-methyl-pyrrolo[2,3-b]pyridine 
• 7546-50-1 2-(2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid 

Relevant articles and documents

Using a Johnson-Claisen Rearrangement Strategy to Construct Azaindoles – A Streamlined and Concise Route for the Commercial Process of Fevipiprant

A novel and concise synthesis of the DP2 receptor antagonist Fevipiprant (NVP-QAW039) was developed. The initial research route was suffering from a long reaction sequence to the functionalized 7-aza-indole core followed by a poorly selective N(1)-alkylat

PREPARATION OF 2-[2-METHYL-1-[[4-METHYLSULFONYL-2-(TRIFLUORO METHYL)PHENYL]METHYL] PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID

The present invention relates to a novel compound of Formula IV and use of said compound for the preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl] methyl]pyrrolo[2,3-b]pyridine-3-yl]acetic acid [fevipiprant], Formula IV wherein A is SO2Me, halogen or a leaving group. The present invention further relates to a process of preparation of pharmaceutical acceptable salts of fevipiprant and composition thereof.

PROCESS FOR PREPARING 1-(4-METHANESULFONYL-2-TRIFLUOROMETHYL-BENZYL)-2-METHYL-1H-PYRROLO [2,3-B]PYRIDIN-3-YL-ACETIC ACID

This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.